文献速递肝病消化道肿瘤与早癌

β-连环蛋白激活的肝细胞癌依赖脂肪酸氧化

β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
PubMed 文献 · Gut · 2018-04-12

该研究利用肝细胞特异性β-连环蛋白致癌激活小鼠模型,发现β-连环蛋白激活的肝细胞癌并非糖酵解型,而是大量氧化脂肪酸;Pparα是β-连环蛋白的靶点并参与脂肪酸氧化代谢重编程,敲除Pparα可阻断β-连环蛋白依赖性肝细胞癌的发生与进展;抑制脂肪酸氧化在遗传学和药理学层面均可阻断肝细胞癌发展,提示抑制脂肪酸氧化是CTNNB1突变型肝细胞癌的潜在治疗策略。

要点

  • β-连环蛋白激活的肝细胞癌依赖脂肪酸氧化而非糖酵解。
  • Pparα是β-连环蛋白靶点,参与脂肪酸氧化代谢重编程。
  • 遗传学或药理学抑制脂肪酸氧化可阻断肝细胞癌发展。

核心结论

  • β-连环蛋白致癌激活诱导的脂肪酸氧化是β-连环蛋白所致肝细胞癌的驱动力。
  • 通过遗传学和药理学方法抑制脂肪酸氧化可阻断肝细胞癌发展,表明抑制脂肪酸氧化是CTNNB1突变型肝细胞癌的合适治疗途径。

研究设计与样本

  • 研究使用肝细胞特异性β-连环蛋白致癌激活小鼠,在肿瘤外植体和原代肝细胞上利用代谢通量评估代谢重编程。
  • 研究在敲除小鼠中评估Pparα的作用,并使用乙莫克舍分析脂肪酸氧化的后果。
  • 研究在注释的人类肝细胞癌数据集中探索脂肪酸氧化通路的表达。

主要发现

  • β-连环蛋白激活的肝细胞癌不是糖酵解型,而是大量氧化脂肪酸。
  • Pparα是β-连环蛋白的靶点,参与脂肪酸氧化代谢重编程。
  • 敲除Pparα足以阻断β-连环蛋白依赖性肝细胞癌的发生与进展。
  • 脂肪酸氧化在人CTNNB1突变型肝细胞癌中也富集,并受转录因子PPARα调控。

临床怎么用

  • 作者认为,抑制脂肪酸氧化是CTNNB1突变型肝细胞癌的合适治疗途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: CTNNB1-mutated hepatocellular carcinomas (HCCs) constitute a major part of human HCC and are largely inaccessible to target therapy. Yet, little is known about the metabolic reprogramming induced by β-catenin oncogenic activation in the liver. We aimed to decipher such reprogramming and assess whether it may represent a new avenue for targeted therapy of CTNNB1-mutated HCC. DESIGN: We used mice with hepatocyte-specific oncogenic activation of β-catenin to evaluate metabolic reprogramming using metabolic fluxes on tumourous explants and primary hepatocytes. We assess the role of Pparα in knock-out mice and analysed the consequences of fatty acid oxidation (FAO) using etomoxir. We explored the expression of the FAO pathway in an annotated human HCC dataset. RESULTS: β-catenin-activated HCC were not glycolytic but intensively oxidised fatty acids. We found that Pparα is a β-catenin target involved in FAO metabolic reprograming. Deletion of Pparα was sufficient to block the initiation and progression of β-catenin-dependent HCC development. FAO was also enriched in human CTNNB1-mutated HCC, under the control of the transcription factor PPARα. CONCLUSIONS: FAO induced by β-catenin oncogenic activation in the liver is the driving force of the β-catenin-induced HCC. Inhibiting FAO by genetic and pharmacological approaches blocks HCC development, showing that inhibition of FAO is a suitable therapeutic approach for CTNNB1-mutated HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Senni N, Savall M, Cabrerizo Granados D, et al. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut. 2018. PMID: 29650531. doi:10.1136/gutjnl-2017-315448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。